The Metabolic Syndrome Prof. Jean-Pierre Després
|
|
- Tamsyn Rich
- 5 years ago
- Views:
Transcription
1 The Metabolic Syndrome 1 Jean-Pierre Després, Ph.D., FAHA, FIAS Quebec Heart and Lung Institute Department of Medicine Université Laval Québec, Canada Reaven s syndrome X Triglycerides HDL cholesterol Insulin resistance Insulin Hypertension 2 Adapted from Reaven GM, Diabetes(1988) 37: CHD odds ratio according to plasma insulin levels and triglyceride or Apo B concentrations in the 5-year follow-up of the Québec Cardiovascular Study Odds ratio 8,0 6,0 4,0 2,0 0, p= p= < >15 Insulin (mu/ml) Odds ratio 15,0 12,0 9,0 6,0 3,0 0, p= p=0.04 < >15 Insulin (mu/ml) Low Triglycerides Low Apo B High Triglycerides High Apo B 3 From Després JP et al. NEJM (1996) 334:
2 Our "toxic" lifestyle 4 The changing landscape of modifiable CVD risk factors Smoking Type 2 diabetes Hypercholesterolemia Abdominal obesity Hypertension Metabolic syndrome Statins HT medication Smoking cessation 5 Sedentariness Energy density of food An early finding from our lab 25 yrs ago! Fat mass: 19.8 kg Visceral AT: 155 cm 2 Fat mass: 19.8 kg Visceral AT: 96 cm 2 6 Obesity cannot be defined by excess body weight/body fat 2
3 Visceral obesity is associated with the cluster of metabolic abnormalities often described as the insulin resistance syndrome Hypertriglyceridemia Low HDL-cholesterol Elevated apolipoprotein B Small, dense LDL particles Inflammatory profile Insulin resistance Hyperinsulinemia Glucose intolerance Impaired fibrinolysis Endothelial dysfunction These features lead to type 2 diabetes and cardiovascular disease 7 Adapted from Lamarche B et al. JAMA (1998) 279: Després JP et al. NEJM (1996) 334: Risk of IHD according to the cumulative number of traditional and non-traditional risk factors Odds ratio* The Québec Cardiovascular Study Traditional risk factors Non-traditional risk factors (0.01) 4.4 (0.01) (<0.001) Traditional: LDL-cholesterol, triglycerides and HDL-cholesterol Non-traditional: Insulin, apolipoprotein B and small, dense LDL particles * Odds ratios are adjusted for systolic blood pressure, family history of IHD and medication use 8 From Lamarche B et al. JAMA (1998) 279: Triglycerides HDL cholesterol Insulin resistance Insulin Hypertension 9 Adapted from Reaven GM, Diabetes(1988) 37:
4 How to find insulin resistant individuals with simple screening tools? The metabolic syndrome a star is born! 10 Clinical identification of the metabolic syndrome according to NCEP-ATP III criteria Waist circumference 1 Men > 102 cm Women > 88 cm Triglycerides mmol/l HDL-cholesterol 3 Men < 1.03 mmol/l Women < 1.29 mmol/l Blood pressure 4 130/85 mm Hg Fasting glucose mmol/l (now 5.6) 11 1 Population-specific cut-off values have been proposed in the International Diabetes Federation guidelines 2 Or treatment for hypertriglyceridemia; 3 Or treatment for low HDL-cholesterol 4 Or treatment for hypertension; 5 Or treatment with a hypoglycemic agent Presence of 3 or more of the above risk determinants Adapted from JAMA (2001) 285: Grundy SM et al. J Am Coll Cardiol(2006) 47: harmonized definition for the clinical identification of the metabolic syndrome 3 risk determinants are present Abdominal obesity Europids Men 94 cm Women 80 cm Non-Europids Men 90 cm Women 80 cm Triglycerides mmol/l HDL-cholesterol 2 Men < 1.0 mmol/l Women < 1.3 mmol/l Blood pressure 3 130/85 mmhg Fasting plasma glucose mmol/l 12 1 Or treated for elevated triglycerides 2 Or treated for low HDL-cholesterol 3 Or treated for hypertension 4 Or treated for elevated fasting plasma glucose Alberti KG, Eckel RH, Grundy SM et al., Circulation (2009) 120:
5 RR of M&M associated with metabolic syndrome (meta-analysis) All cause death No. studies 6 RR (95 % CI) 1.35 ( ) CVD death ( ) CVD CHD ( ) 1.52 ( ) Stroke ( ) 13 Adapted from Galassi A et al., Am J Med (2006) 119: Metabolic syndrome: some issues Clinical evaluation vs. definition (pathophysiology) Heterogeneous (3 out of 5 criteria) Yes or no: does not assess its severity Cannot assess absolute CVD risk As an entity, cannot be a therapeutic target Added value? 14 Després JP, Cartier A, Côté M, Arsenault BJ. Ann Med.(2008) 40(7): A Genetic and environmental determinants Energy dense diet Genetic variation Age and Gender Lack of physical activity Smoking Stress Neuroendocrine abnormalities Steroid hormones Susceptible endocannabinoid system Drugs B Visceral obesity/ Ectopic fat Adipokines Insulin resistance/ Insulin Impaired Inflammation fibrinolysis Syndrome X (Reaven) Insulin resistance syndrome Blood pressure Atherogenic dyslipidemia Dysglycemia Based on key pathophysiological markers C 15 Metabolic syndrome (NCEP-ATP III or IDF) Based on clinical tools: Waist girth Triglycerides HDL-cholesterol Glucose Blood pressure Després JP et al., ATVB (2008)28:
6 How prevalent is the metabolic syndrome among nonobese individuals? 16 Waist girth among men of the Québec Health Survey characterized by different combinations of features of the metabolic syndrome (NCEP-ATPIII) Waist girth > 102 cm X X X X X X Triglycerides 1.7 mmol/l X X X X HDL cholesterol < 1.03 mmol/l X X X X Blood pressure 130/85 mmhg X X X Fasting glucose 6.1 mmol/l X X X X Waist girth (cm) X X X X X X X X X 17 From Després JP, et al., Eur Heart J (2008) 10(Suppl B): B24-B
7 Abdominal obesity is the most prevalent form of the metabolic syndrome Endothelial dysfunction Atherogenic dyslipidemia Hypertension ( ( Inflammatory profile Insulin resistance Pro-thrombotic state 19 From Després JP, Lemieux I. Nature (2006) 444: Excess liver fat: another characteristic of visceral obesity associated with features of the metabolic syndrome 20 Liver fat: an important partner in crime in the link between visceral fat and cardiometabolic risk? Increased liver fat deposition Positive energy balance? Expanded visceral fat depot Cardiometabolic risk 21 Source: International Chair on Cardiometabolic Risk 7
8 22 From Guerrero R. et al., Hepatology (2009)49: Sex differences in liver fat content are largely explained by differences in visceral adiposity Figure 3. Relationship Between Hepatic Triglyceride Content and Total/Regional Adiposity by Gender Hepatic triglyceride content (HTGC) was log transformed to meet assumptions of ANCOVA analysis. As expected, HTGC increased as a function of total and regional adiposity in both sexes. (A) The plot of HTGC vs. percent body fat (%BF) in men and women. The slopes of this relationship were significantly different (Slopemen 0.06 vs. Slopewomen 0.05 P=0.019). (B) The plot of HTGC vs. percent intraperitoneal fat (%IP) (intraperitoneal fat mass / total body mass) in men and women. The slopes of this relationship were significantly different (Slopeme n 0.66 vs. Slopewomen, 0.81 P=0.022). Adjustment for subcutaneous fat yielded resultssimilar to adjustment for %BF. 23 From Guerrero R. et al., Hepatology (2009)49: There is, however, a lack of international data on the contribution of excess visceral adiposity/liver fat to the cardiometabolic risk profile of patients with: Impaired glucose homeostasis Type 2 diabetes Cardiovascular disease 24 8
9 25 Adapted from Smith JD et al., J Clin Endocrinol Metab (2012)97(5): Overall objectives of INSPIRE ME IAA 26 Cross-sectionally: To determine the relationship between visceral adiposity and: Cardiometabolic risk markers/factors including waist circumference History of ischemic cardiovascular events and type 2 diabetes Prospectively: To determine the relationship between visceral adiposity and incidence of ischemic cardiovascular events and type 2 diabetes over a 3-year follow-up period General information 29 countries; 4277 patients ( 52%; 48%) First patients in: 30 June 2006, last patient in: 30 May 2008 North America n=701 patients Latin America n=885 patients Asia n=1636 patients Europe n=1055 patients Mean age: 57 years Hypertension: 60% Type 2 diabetes fasting glucose 7 mmol/l or glucose 11.1 mmol/l 120 or treatment for diabetes or history of diabetes: 39% Metabolic syndrome (AHA/NHLBI): 62% Cardiovascular disease (CAD, CRVD, PAD): 24% 27 9
10 Visceral adipose tissue measurement Vertebrae Ribs L4-L5 Muscle Visceral fat Visceral fat Visceral fat Subcutaneous fat Subcutaneous fat 28 L4-L5 inter-vertebral space Liver fat measurement (Th12-L1) Subject A Lean liver CTL-Liver Liver fat CTS-Spleen CTL: 79.4 HU CTS: 59.6 HU Subject B Fatty liver Liver attenuation value (CTL) CTL: 14.8 HU CTS: 60.7 HU 29 Visceral Adiposity Type 2 Diabetes Cardiometabolic risk? 30 10
11 Categorization by presence/absence of type 2 diabetes and tertiles of VAT 1 st tertile of VAT: low VAT Low VAT without T2D (386 m, 457 w) Low VAT with T2D (273 m, 149 w) All patients (with and without T2D) 2 nd tertile of VAT: mid VAT Mid VAT without T2D (356 m, 334 w) Mid VAT with T2D (309 m, 252 w) 31 3 rd tertile of VAT: high VAT High VAT without T2D (258 m, 221 w) High VAT with T2D (403 m, 371 w) Triglyceride concentrations across visceral adipose tissue tertiles in men without and with type 2 diabetes Triglycerides (mmol/l) Without type 2 diabetes With type 2 diabetes >204.9 Visceral adipose tissue tertiles (cm 2 ) p< for visceral AT, p=0.6 for type 2 diabetes, p=0.2 for interaction 32 Adapted from Smith JD et al., J Clin Endocrinol Metab (2012)97(5): Triglyceride concentrations across visceral adipose tissue tertiles in women without and with type 2 diabetes Triglycerides (mmol/l) Without type 2 diabetes With type 2 diabetes >167.3 Visceral adipose tissue tertiles (cm 2 ) 33 p< for visceral AT, p< for type 2 diabetes, p=0.002 for interaction Adapted from Smith JD et al., J Clin Endocrinol Metab (2012)97(5):
12 HDL cholesterol concentrations across visceral adipose tissue tertiles in men without and with type 2 diabetes HDl cholesterol (mmol/l) Without type 2 diabetes With type 2 diabetes >204.9 Visceral adipose tissue tertiles (cm 2 ) 34 p< for visceral AT, p=0.05 for type 2 diabetes, p=0.6 for interaction Adapted from Smith JD et al., J Clin Endocrinol Metab (2012)97(5): HDL cholesterol concentrations across visceral adipose tissue tertiles in women without and with type 2 diabetes HDl cholesterol (mmol/l) Without type 2 diabetes With type 2 diabetes >167.3 Visceral adipose tissue tertiles (cm 2 ) 35 p< for visceral AT, p< for type 2 diabetes, p= for interaction Adapted from Smith JD et al., J Clin Endocrinol Metab (2012)97(5): Inflammatory factors increased with both visceral adiposity and type 2 diabetes Men lowvat medvat highvat lowvat medvat highvat Type 2 diabetes No diabetes 36 lowvat medvat highvat Adjusted for: age, physician s specialty, region, BMI There was a similar pattern in women 12
13 Liver fat was related to both visceral adiposity and type 2 diabetes Men Women lowvat midvat highvat lowvat midvat highvat 37 Adjusted for age, physician s specialty, region, BMI Type 2 diabetes No diabetes Frequency of prevalent CVD in men and women without and with type 2 diabetes A Men Women lowvat midvat highvat lowvat midvat highvat CVD: history of current symptoms of carotid revascularization, carotid stenosis, lower limb amputation due to ischemic disease, lower limb revascularization, myocardial infarction or unstable angina, myocardial revascularization, or stroke Statistical significance was calculated using a logistic model including VAT tertiles, type 2 diabetes status, and their interaction as well as age, BMI, patient s geographical region, and the recruiting physician s specialty 38 Adapted from Smith JD et al., J Clin Endocrinol Metab (2012)97(5): Odds ratios for type 2 diabetes associated with a 1-SD change in cardiometabolic risk factors C Men Statistical model 2 D Women Statistical model 2 SBP SBP DPB log (TG) HDL-C SAT VAT liver attenuation DPB log (TG) HDL-C SAT liver attenuation VAT Men and women report odds ratios after adjustment for one another as well as for the following confounding variables: Age, geographical region, and recruiting physician s specialty 39 Adapted from Smith JD et al., J Clin Endocrinol Metab (2012)97(5):
14 Conclusion Visceral Adiposity Type 2 Diabetes 40 Cardiometabolic risk? Excess visceral adiposity/liver is a key correlate of metabolic abnormalities in both patients with/without type 2 diabetes Excess visceral/liver fat redefines what is high risk overweight/obesity Increased liver fat deposition Positive energy balance? Expanded visceral fat depot Cardiometabolic risk 41 Source: International Chair on Cardiometabolic Risk Visceral obesity = dysfunctional adipose tissue? A Insulin resistant Portal circulation Altered FFA metabolism Hyperinsulinemia Glucose intolerance Hypertriglyceridemia Etc. B Release of cytokines IL-6 TNF-a Adiponectin Other adipokines Altered metabolic profile: Insulin resistant milieu Pro-inflammatory state Pro-thrombotic state Pro-hypertensive state C Ectopic fat deposition 42 Lack of or dysfunctional subcutaneous fat Impaired Clearance and storage of TG in subcutaneous AT From Després JP, Lemieux I. Nature (2006)444: ,Després JP et al., ATVB (2008)28:
15 How to find insulin resistant individuals with excess visceral adipose tissue/liver fat with simple screening tools? «Hypertriglyceridemic waist» 43 Hypertriglyceridemic waist as a screening tool for visceral obesity/ectopic fat Waist* + Triglycerides* Good < 90 cm < 2.0 mmol/l ~10% Bad > 90 cm > 2.0 mmol/l ~80% * 85 cm and 1.5 mmol/l in women 44 Adapted from Lemieux I et al., Circulation(2000) 102: HyperTG waist and CHD risk in the EPIC-Norfolk Study PIs: Wareham NJ, Khaw KT (Cambridge) European Prospective Investigation into Cancer and nutrition - Norfolk study 21,758 subjects (9,496 men and 12,262 women) aged 45 to 79 years Mean follow-up 8.2 ± 1.4 years 1387 CHD events (854 men and 533 women) 45 Arsenault B et al, CMAJ. (2010) 183:
16 Without Hypertriglyceridemic waist: an important clinical phenotype in men of the EPIC-Norfolk study Systolic BP With Without Diastolic BP With 1,5 1,4 1,3 1,2 1,1 1,0 HDL-cholesterol Without With CRP LDL particle size Apolipoprotein B 4,0 3,5 p= , , ,0 46 Without With 250 Without 110 With Without With Arsenault B et al, CMAJ. (2010) 183: Without Hypertriglyceridemic waist: an important clinical phenotype in women of the EPIC-Norfolk study Systolic BP With Without Diastolic BP With 2,0 1,8 1,6 1,4 1,2 1,0 HDL-cholesterol Without With CRP LDL particle size Apolipoprotein B 6,0 5, ,0 3, ,0 47 Without With 250 Without 110 With Without With Arsenault B et al, CMAJ. (2010) 183: Kaplan-Meir survival curves according to subgroups of hypertriglyceridemic waist in men ( ) 1.00 Men Event-free survival WC<90 cm, TG<2.0 mmol/l WC<90 cm, TG>2.0 mmol/l WC>90 cm, TG<2.0 mmol/l WC>90 cm, TG>2.0 mmol/l Follow-up (years) 48 Arsenault B et al, CMAJ. (2010) 183:
17 Kaplan-Meir survival curves according to subgroups of hypertriglyceridemic waist in women ( ) 1.00 Women Event-free survival WC<85 cm, TG<1.5 mmol/l WC<85 cm, TG>1.5 mmol/l WC>85 cm, TG<1.5 mmol/l WC>85 cm, TG>1.5 mmol/l Follow-up (years) 49 Arsenault B et al, CMAJ. (2010) 183: Limitations of a clinical diagnosis of the metabolic syndrome in absolute CVD risk assessment 50 CASE #1 Nondiabetic man 30 years of age Normal blood pressure Nonsmoker Waist circumference = 104 cm Triglycerides = 2.50 mmol/l LDL-cholesterol = 3.00 mmol/l HDL-cholesterol = 0.85 mmol/l 51 Framingham 10-year CHD risk= 4% Metabolic syndrome 10-year CHD risk 8 4 Relative risk of CHD by 2 fold Relative risk of CHD 2X 0 Absence Presence Metabolic syndrome From Després JP, Lemieux I. Nature (2006) 444: CASE #2 Nondiabetic man 55 years of age Blood pressure = 170/95 mmhg Smoker Waist circumference = 104 cm Triglycerides = 2.50 mmol/l LDL-cholesterol = 4.00 mmol/l HDL-cholesterol = 0.85 mmol/l Framingham 10-year CHD risk= 33% Metabolic syndrome 10-year CHD risk Relative risk of CHD Relative risk of CHD by 2 fold 2X 0 AbsencePresence Metabolic syndrome 17
18 Risk of CHD associated with the metabolic syndrome: relative risk vs. absolute risk 52 Absolute 10-year CHD risk (%) AbsencePresence AbsencePresence Metabolic syndrome? Metabolic syndrome Case #1 Case #2 From Després JP, Lemieux I. Nature (2006) 444: Metabolic syndrome: one component of global CMR + = 53 From Després JP, Lemieux I. Nature (2006) 444: Incorporating visceral adiposity/ectopic fat into improved global risk assessment algorithms? HyperTG-waist Visceral Ectopic fat Insulin resistance LDL HDL Hypertension Diabetes Age Male gender Smoking Others (genetic factors) Global cardiometabolic risk 54 From Després JP, Lemieux I. Nature (2006) 444:
19 Management of the metabolic syndrome: the medical approach 55 We have good news your cholesterol is normal!" "Turbostatins": the medical response to our sedentary atherogenic/pro-inflammatory lifestyle? 56 From Després JP. The Lancet(2009) 379: The abdominally obese patient most often has a sedentary lifestyle and a poor fitness level 57 19
20 58 Men Women * * ** * * ** 59 Broekhuizen LN et al, Eur J Cardiovasc Prev Rehab (2011) 18: Relative CHD risk Low cardiorespiratory fitness: a powerful CHD risk factor ,120 women, 10,224 men ~ 8-year follow-up Low High Fitness level Women Low High Fitness level Men From Blair SN et al., JAMA (1989) 262:
21 61 Reshaping lifestyle habits of viscerally obese patients with features of the metabolic syndrome 62 What should our target be? Loss of visceral/liver fat and improving cardiorespiratory fitness? The metabolic syndrome Which variables/factors should be on our radar screen? Lifestyle variables ( the causes of the causes ) Nutritional quality Physical activity/exercise, sedentary time Ecological, socio-economic drivers of unhealthy behaviors Phenotypes: Imaging markers of visceral/ectopic fat Physical activity (pedometers, accelerometers with HR) Cardiorespiratory fitness Anthropometry, blood markers (IR, lipoproteins, inflammation) 63 21
22 64 22
Cardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationMetabolic Syndrome: An overview. Kevin Niswender MD, PhD Vanderbilt University School of Medicine
Metabolic Syndrome: An overview. Kevin Niswender MD, PhD Vanderbilt University School of Medicine Setting the scene GB, 43 yo AA man followed for hypothyroidism returns on LT4 125 mcg/d and has a TSH=1.1
More informationThe Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk
Update 2013 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine Denver Health
More informationMetabolic Syndrome in Asians
Metabolic Syndrome in Asians Alka Kanaya, MD Asst. Professor of Medicine, UCSF Asian CV Symposium, November 17, 2007 The Metabolic Syndrome Also known as: Syndrome X Insulin Resistance Syndrome The Deadly
More informationRoadmap. Diabetes and the Metabolic Syndrome in the Asian Population. Asian. subgroups 8.9. in U.S. (% of total
Diabetes and the Metabolic Syndrome in the Asian Population Alka Kanaya, MD Associate Professor of Medicine, UCSF Feb 26, 2010 Roadmap 1. Diabetes in Asian Americans Prevalence in the U.S. Risk factors
More informationMetabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk
Metabolic Syndrome Update 21 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes University of Colorado Denver Denver Health Medical Center The Metabolic
More informationThe Metabolic Syndrome Update The Metabolic Syndrome Update. Global Cardiometabolic Risk
The Metabolic Syndrome Update 2018 Marc Cornier, M.D. Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine
More informationThe Metabolic Syndrome: Is It A Valid Concept? YES
The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA
More informationObesity, Metabolic Syndrome, and Diabetes: Making the Connections
Obesity, Metabolic Syndrome, and Diabetes: Making the Connections Alka M. Kanaya, M.D. Associate Professor of Medicine & Epi/Biostats University of California, San Francisco February 26, 21 Roadmap 1.
More informationEpidemiology of Diabetes, Impaired Glucose Homeostasis and Cardiovascular Risk. Eberhard Standl
Epidemiology of Diabetes, Impaired Glucose Homeostasis and Cardiovascular Risk Eberhard Standl European Heart House Sophia Antipolis Thursday, June 17, 2010 IDF Diabetes Atlas 2009: Global Numbers Still
More informationMetabolic Syndrome: Why Should We Look For It?
021-CardioCase 29/05/06 15:04 Page 21 Metabolic Syndrome: Why Should We Look For It? Dafna Rippel, MD, MHA and Andrew Ignaszewski, MD, FRCPC CardioCase presentation Andy s fatigue Andy, 47, comes to you
More informationMetabolic syn and CVD. Dr : dehestani Imam reza hospital
Metabolic syn and CVD { Dr : dehestani Imam reza hospital Global Distribution of CVDs as Causes of Death, WHO 2011 Worldwide Mortality from Ischemic Heart Disease and Cerebrovascular Disease 2011 Ischemic
More informationHigh levels of plasma triglycerides (TGs) are a risk factor for
TriglycerideYtoYHigh-Density-Lipoprotein-Cholesterol Ratio Is an Index of Heart Disease Mortality and of Incidence of Type 2 Diabetes Mellitus in Men Gloria Lena Vega, PhD,* Carolyn E. Barlow, MS,Þ Scott
More informationFasting or non fasting?
Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues
More informationMetabolic Syndrome. Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah
Metabolic Syndrome Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah Objectives Be able to outline the pathophysiology of the metabolic syndrome Be able to list diagnostic criteria for
More informationTotal risk management of Cardiovascular diseases Nobuhiro Yamada
Nobuhiro Yamada The worldwide burden of cardiovascular diseases (WHO) To prevent cardiovascular diseases Beyond LDL Multiple risk factors With common molecular basis The Current Burden of CVD CVD is responsible
More informationContents. I. CV disease and insulin resistance: Challenges and opportunities. II. Insulin sensitizers: Surrogate and clinical outcomes studies
Contents I. CV disease and insulin resistance: Challenges and opportunities II. Insulin sensitizers: Surrogate and clinical outcomes studies IV. Identifying and treating patients with insulin resistance
More informationCVD Prevention, Who to Consider
Continuing Professional Development 3rd annual McGill CME Cruise September 20 27, 2015 CVD Prevention, Who to Consider Dr. Guy Tremblay Excellence in Health Care and Lifelong Learning Global CV risk assessment..
More informationVALVULO-METABOLIC RISK IN AORTIC STENOSIS
January 2008 (Vol. 1, Issue 1, pages 21-25) VALVULO-METABOLIC RISK IN AORTIC STENOSIS By Philippe Pibarot, DVM, PhD, FACC, FAHA Groupe de Recherche en Valvulopathies (GRV), Hôpital Laval Research Centre
More informationThe promise of the thiazolidinediones in the management of type 2 diabetes-associated cardiovascular disease
The promise of the thiazolidinediones in the management of type 2 diabetes-associated cardiovascular disease Steve Smith, Group Director Scientific Affairs, Diabetes & Metabolism GlaxoSmithKline R & D
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More information3/20/2011. Body Mass Index (kg/[m 2 ]) Age at Issue (*BMI > 30, or ~ 30 lbs overweight for 5 4 woman) Mokdad A.H.
U.S. Adults: 1988 Nineteen states with 10-14% 14% Prevalence of Obesity (*BMI > 30, or ~ 30 lbs overweight for 5 4 woman) Metabolic John P. Cello, MD Professor of Medicine and Surgery, University of California,
More informationDiabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology
Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology Disclosures In compliance with the accrediting board policies, the American Diabetes Association requires the
More informationThe Metabolic Syndrome
The Metabolic Syndrome Advances in Internal Medicine David D. Waters, MD May 21, 27 UCSF Metabolic Syndrome: Definition abdominal obesity increased waist circumference atherogenic dyslipidemia low HDL-C,
More informationMetabolic Syndrome.
www.bmiweightloss.com.au What is the metabolic syndrome? The was first described in 1988 by Gerald Reavson It was originally described as the clustering of four conditions These conditions when present
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationCARDIOMETABOLIC SYNDROME
CARDIOMETABOLIC SYNDROME Prof. Gerald Yonga FESC, FACC Dept of Medicine, Aga Khan University East Africa Introduction Years after the term metabolic syndrome was first coined, controversy continues over
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationMarshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationRisk Factors for Heart Disease
Risk Factors for Heart Disease Risk Factors we cannot change (Age, Gender, Family History) Risk Factors we can change (modifiable) Smoking Blood pressure Cholesterol Diabetes Inactivity Overweight Stress
More informationMetabolic Syndrome: What s in a name?
Commentary Metabolic Syndrome: What s in a name? Deborah P. Wubben, MD, MPH; Alexandra K. Adams, MD, PhD Abstract The term metabolic syndrome has recently become en vogue. But is the definition realistic,
More informationCardiovascular risk assessment in the metabolic syndrome: results from the Prospective Cardiovascular Munster (PROCAM) Study
(28) 32, S11 S16 & 28 Nature Publishing Group All rights reserved 37-6/8 $3. www.nature.com/ijo ORIGINAL ARTICLE Cardiovascular risk assessment in the metabolic syndrome: results from the Prospective Cardiovascular
More information2.5% of all deaths globally each year. 7th leading cause of death by % of people with diabetes live in low and middle income countries
Lipid Disorders in Diabetes (Diabetic Dyslipidemia) Khosrow Adeli PhD, FCACB, DABCC Head and Professor, Clinical Biochemistry, The Hospital for Sick Children, University it of Toronto Diabetes A Global
More informationThe metabolic syndrome has received increased attention
AHA/NHLBI Scientific Statement Diagnosis and Management of the Metabolic Syndrome An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement Scott M. Grundy, MD, PhD,
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationTesamorelin Clinical Data Overview Jean-Claude Mamputu, PhD Senior Medical Advisor, Theratechnologies
Tesamorelin Clinical Data Overview Jean-Claude Mamputu, PhD Senior Medical Advisor, Theratechnologies Copyright 2016. All Rights Reserved. Property of Theratechnologies Inc. Mechanism of Action of Tesamorelin
More informationApproach to Dyslipidemia among diabetic patients
Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationSoo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital
Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital 1. Importance of Lowering LDL-Cholesterol in Diabetes Patients & Lipid Guidelines Prevalence of dyslipidemia in Korea Prevalence
More informationEstablished Risk Factors for Coronary Heart Disease (CHD)
Getting Patients to Make Small Lifestyle Changes That Result in SIGNIFICANT Improvements in Health - Prevention of Diabetes and Obesity for Better Health Maureen E. Mays, MD, MS, FACC Director ~ Portland
More informationBehind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL
Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Sung-Joon Lee, PhD Division of Food Science Institute of Biomedical Science and Safety Korea University Composition of Lipoproteins:
More informationOptimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden
Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD
More informationObesity in the pathogenesis of chronic disease
Portoroz October 16th 2013 Obesity in the pathogenesis of chronic disease Rocco Barazzoni University of Trieste Department of Medical, Surgical and Health Sciences Obesity Trends* Among U.S. Adults BRFSS,
More informationABSTRACT. Dr. Jiuzhou Song, Department of Avian and Animal Sciences. Blacks in the country suffer from higher prevalences of obesity, diabetes,
ABSTRACT Title of Document: IS THE CURRENT DEFINITION OF THE METABOLIC SYNDROME A USEFUL TOOL FOR THE DETECTION OF CARDIOVASCULAR DISEASE IN NON- HISPANIC BLACKS? Omayra I. Rodriguez, Masters in Science,
More informationCardiovascular Complications in Diabetes
What is all the fuss about? Cardiovascular Complications in Diabetes Dina Shrestha MD Consultant Endocrinologist Norvic International Hospital and Medical College Hospital for Advanced Medicine and Surgery
More informationDiscussion points. The cardiometabolic connection. Cardiometabolic Risk Management in the Primary Care Setting
Session #5 Cardiometabolic Risk Management in the Primary Care Setting Sonja Reichert, MD MSc FCFP FACPM Betty Harvey, RNEC BScN MScN Amanda Mikalachki, RN BScN CDE S Discussion points Whom should we be
More informationHypertension with Comorbidities Treatment of Metabolic Risk Factors in Children and Adolescents
Hypertension with Comorbidities Treatment of Metabolic Risk Factors in Children and Adolescents Stella Stabouli Ass. Professor Pediatrics 1 st Department of Pediatrics Hippocratio Hospital Evaluation of
More informationAccelerated atherosclerosis begins years prior to the diagnosis of diabetes
Joslin Diabetes Forum 211: Optimizing Care for the Practicing Clinician Risk for atherosclerosis is 2 4 times greater in patients with diabetes CVD accounts for 65% of diabetic mortality >5% of patients
More informationMETABOLIC SYNDROME IN OBESE CHILDREN AND ADOLESCENTS
Rev. Med. Chir. Soc. Med. Nat., Iaşi 2012 vol. 116, no. 4 INTERNAL MEDICINE - PEDIATRICS ORIGINAL PAPERS METABOLIC SYNDROME IN OBESE CHILDREN AND ADOLESCENTS Ana-Maria Pelin 1, Silvia Mǎtǎsaru 2 University
More informationThere are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?
There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationMetabolic syndrome. Metabolic syndrome and prediabetes appear to be the same disorder, just diagnosed by a different set of biomarkers.
Metabolic syndrome Metabolic syndrome is a disorder of energy utilization and storage, diagnosed by a co-occurrence of three out of five of the following medical conditions: abdominal (central) obesity,
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More information5/28/2010. Pre Test Question
Myth of Metabolic Syndrome? C. W. Spellman, DO, PhD Professor and Associate Dean Research Dir. Center Diabetes and Metabolic Disorders Department Internal Medicine, Div. Endocrinology Texas Tech University
More informationBackground. Metabolic syndrome T2DM CARDIOVASCULAR DISEASE. Major Unmet Clinical Need. Novel Risk Factors. Classical Risk Factors LDL-C.
The effect of metabolic syndrome for left ventricular geometry, arterial stiffness and carotid intima-media thickness in Korean general population Result from Atherosclerosis RIsk of Rural Area in Korea
More informationWelcome and Introduction
Welcome and Introduction This presentation will: Define obesity, prediabetes, and diabetes Discuss the diagnoses and management of obesity, prediabetes, and diabetes Explain the early risk factors for
More informationTHE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS
THE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS Hormonal regulation INSULIN lipid synthesis, lipolysis CORTISOL lipolysis GLUCAGON lipolysis GROWTH HORMONE lipolysis CATECHOLAMINES lipolysis LEPTIN catabolism
More informationEnvironmental. Vascular / Tissue. Metabolics
Global Risk Reduction--WINS Picking Mom and Dad-2016 Environmental Vascular / Tissue Metabolics Stop smoking-1b Physical activity-1b Weight control-1b Chelation therapy-3c Influenza vaccination-1b Blood
More informationGuidelines on cardiovascular risk assessment and management
European Heart Journal Supplements (2005) 7 (Supplement L), L5 L10 doi:10.1093/eurheartj/sui079 Guidelines on cardiovascular risk assessment and management David A. Wood 1,2 * 1 Cardiovascular Medicine
More informationImplications of The LookAHEAD Trial: Is Weight Loss Beneficial for Patients with Diabetes?
Implications of The LookAHEAD Trial: Is Weight Loss Beneficial for Patients with Diabetes? Boston, MA November 7, 213 Edward S. Horton, MD Professor of Medicine Harvard Medical School Senior Investigator
More information2/11/2017. Weighing the Heavy Cardiovascular Burden of Obesity and the Obesity Paradox. Disclosures. Carl J. Lavie, MD, FACC, FACP, FCCP
Weighing the Heavy Cardiovascular Burden of Obesity and the Obesity Paradox Carl J. Lavie, MD, FACC, FACP, FCCP Professor of Medicine Medical Director, Cardiac Rehabilitation and Preventive Cardiology
More informationCase Study: Chris Arden. Peripheral Arterial Disease
Case Study: Chris Arden Peripheral Arterial Disease Patient Presentation Diane is a 65-year-old retired school teacher She complains of left calf pain when walking 50 metres; the pain goes away after she
More informationNon alcoholic fatty liver disease and atherosclerosis Raul Santos, MD
Non alcoholic fatty liver disease and atherosclerosis Raul Santos, MD Sao Paulo Medical School Hospital Sao Paulo, Brazil Disclosure Honoraria received for consult and/or speaker : Astra Zeneca, Amgen,
More informationAssessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients. Copyright. Not for Sale or Commercial Distribution
CLINICAL Viewpoint Assessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients Copyright Not for Sale or Commercial Distribution By Ruth McPherson, MD, PhD, FRCPC Unauthorised
More informationPIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia
PIEDMONT ACCESS TO HEALTH SERVICES, INC. Policy Number: 01-09-021 SUBJECT: Guidelines for Screening and Management of Dyslipidemia EFFECTIVE DATE: 04/2008 REVIEWED/REVISED: 04/12/10, 03/17/2011, 4/10/2012,
More informationCardiovascular Disease After Spinal Cord Injury: Achieving Best Practice. Suzanne Groah, MD, MSPH Walter Reed Army Medical Center February 12, 2010
Cardiovascular Disease After Spinal Cord Injury: Achieving Best Practice Suzanne Groah, MD, MSPH Walter Reed Army Medical Center February 12, 2010 CAVEAT LECTOR 2 CVD-related Mortality in Aging SCI GU
More informationChapter 2 The Metabolic Syndrome
Chapter 2 The Metabolic Syndrome Matthew J. Sorrentino Keywords Waist circumference Abdominal obesity Impaired fasting glucose HDL-cholesterol Triglycerides Metabolic syndrome is the designation given
More informationHSN301 REVISION NOTES TOPIC 1 METABOLIC SYNDROME
HSN301 REVISION NOTES TOPIC 1 METABOLIC SYNDROME What does the term Metabolic Syndrome describe? Metabolic syndrome describes a cluster of cardio-metabolic conditions that increase one's risk of developing
More informationDiabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
More informationWhat Else Do You Need to Know? Presenter Disclosure Information. Case 1: Cardiovascular Risk Assessment in a 53-Year-Old Man. Learning Objectives
9: 1:am Understanding Dyslipidemia Testing and Screening: Importance of Lipoprotein Particle Analysis SPEAKER Matthew Sorrentino, MD, FACC Presenter Disclosure Information The following relationships exist
More informationMetabolic Syndrome among Type-2 Diabetic Patients in Benghazi- Libya: A pilot study. Arab Medical University. Benghazi, Libya
Original Article Metabolic Syndrome among Type-2 Diabetic Patients in Benghazi- Libya: A pilot study Alshkri MM 1, Elmehdawi RR 2 1 Benghazi Diabetes Center. 2 Medical Department, Faculty of Medicine,
More information(n=6279). Continuous variables are reported as mean with 95% confidence interval and T1 T2 T3. Number of subjects
Table 1. Distribution of baseline characteristics across tertiles of OPG adjusted for age and sex (n=6279). Continuous variables are reported as mean with 95% confidence interval and categorical values
More informationModule 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension
Module 2 Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension 1 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,
More informationDyslipidaemia. Is there any new information? Dr. A.R.M. Saifuddin Ekram
Dyslipidaemia Is there any new information? Dr. A.R.M. Saifuddin Ekram PhD,FACP,FCPS(Medicine) Professor(c.c.) & Head Department of Medicine Rajshahi Medical College Rajshahi-6000 New features of ATP III
More informationHow to Reduce Residual Risk in Primary Prevention
How to Reduce Residual Risk in Primary Prevention Helene Glassberg, MD Assistant Professor of Medicine Section of Cardiology Hospital of the University of Pennsylvania Philadelphia, PA USA Patients with
More informationMOLINA HEALTHCARE OF CALIFORNIA
MOLINA HEALTHCARE OF CALIFORNIA HIGH BLOOD CHOLESTEROL IN ADULTS GUIDELINE Molina Healthcare of California has adopted the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel
More informationDavid Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon
David Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon I have no actual or potential conflicts of interest in relation to this program or presentation. Raphael School of Athens, 1509-1511 Apply
More informationNon-fasting Lipid Profile Getting to the Heart of the Matter! Medimail Dec 2017
Non-fasting Lipid Profile Getting to the Heart of the Matter! Medimail Dec 2017 Historical Basis for Fasting Lipids The initial classifications of hyperlipidemia proposed in 1967 were genetic and required
More informationCase Presentation. Moderator: Sharon Liu, DO Associate Internal Medicine Chief Austin Regional Clinic Austin, Texas
Case Presentation Moderator: Sharon Liu, DO Associate Internal Medicine Chief Austin Regional Clinic Austin, Texas Izzy (2006) 51 y/o Hispanic woman with a history of diabetes and obesity. Her diabetes
More informationCardiometabolics in Children or Lipidology for Kids. Stanley J Goldberg MD Diplomate: American Board of Clinical Lipidology Tucson, Az
Cardiometabolics in Children or Lipidology for Kids Stanley J Goldberg MD Diplomate: American Board of Clinical Lipidology Tucson, Az No disclosures for this Presentation Death Risk Approximately 40% of
More informationTreatment to reduce cardiovascular risk: multifactorial management
Treatment to reduce cardiovascular risk: multifactorial management Matteo Anselmino, MD PhD Assistant Professor San Giovanni Battista Hospital Division of Cardiology, Department of Internal Medicine University
More informationUpdate On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID?
Update On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID? Karen Aspry, MD, MS, ABCL, FACC Assistant Clinical Professor of Medicine Warren Alpert Medical School of Brown
More informationEyes on Korean Data: Lipid Management in Korean DM Patients
Eyes on Korean Data: Lipid Management in Korean DM Patients ICDM Luncheon Symposium Sung Rae Kim MD PhD Division of Endocrinology and Metabolism The Catholic University of Korea Causes of Death in People
More informationProf. John Chapman, MD, PhD, DSc
Prof. John Chapman, MD, PhD, DSc Director of the Dyslipidemia and Atherosclerosis Research Unit of the National Institute for Health and Medical Research (INSERM) at the Pitié-Salpétrière Hospital in Paris
More informationJournal of the American College of Cardiology Vol. 48, No. 2, by the American College of Cardiology Foundation ISSN /06/$32.
Journal of the American College of Cardiology Vol. 48, No. 2, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.03.043
More informationEstablishment of Efficacy of Intervention in those with Metabolic Syndrome. Dr Wendy Russell - ILSI Europe Expert Group
Establishment of Efficacy of Intervention in those with Metabolic Syndrome Dr Wendy Russell - ILSI Europe Expert Group Conflict of interest regarding this presentation: I have no conflict of interest to
More informationPathophysiology of Lipid Disorders
Pathophysiology of Lipid Disorders Henry Ginsberg, M.D. Division of Preventive Medicine and Nutrition CHD in the United States CHD is the single largest killer of men and women 12 million have history
More informationJoslin Diabetes Center Primary Care Congress for Cardiometabolic Health 2013 The Metabolic Syndrome: Is It a Valid Concept?
The Metabolic Syndrome: A Defeated Emperor What were (are) the problems? Well 1. There was no agreed upon pathogenic reason to identify people with the metabolic syndrome 2. It was a relatively poor way
More information2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD
2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD How do you interpret my blood test results? What are our targets for these tests? Before the ACC/AHA Lipid Guidelines A1c:
More information3/25/2010. Age-adjusted incidence rates for coronary heart disease according to body mass index and waist circumference tertiles
Outline Relationships among Regional Adiposity, Physical Activity, and CVD Risk Factors: Preliminary Results from Two Epidemiologic Studies Molly Conroy, MD, MPH Obesity Journal Club February 18, 2010
More informationThe IDF consensus worldwide definition of the metabolic syndrome
International Diabetes Federation Avenue Emile De Mot 19 B-1000 Brussels, Belgium Telephone +32-2-5385511 Telefax +32-2-5385114 info@idf.org www.idf.org VAT BE433.674.528 The IDF consensus worldwide definition
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More informationGlobal Coronary Heart Disease Risk Assessment of U.S. Persons With the Metabolic. Syndrome. and Nathan D. Wong, PhD, MPH
Diabetes Care Publish Ahead of Print, published online April 1, 2008 Global Coronary Heart Disease Risk Assessment of U.S. Persons With the Metabolic Syndrome Khiet C. Hoang MD, Heli Ghandehari, BS, Victor
More informationMethods. Background and Objectives STRADIVARIUS
STRADIVARIUS Effect of on Progression of Atherosclerosis in Patients with Abdominal Obesity and Coronary Artery Disease Steven E. Nissen MD Stephen J. Nicholls MBBS PhD, Kathy Wolski MPH, Josep Rodés-Cabau
More informationCentral pressures and prediction of cardiovascular events in erectile dysfunction patients
Central pressures and prediction of cardiovascular events in erectile dysfunction patients N. Ioakeimidis, K. Rokkas, A. Angelis, Z. Kratiras, M. Abdelrasoul, C. Georgakopoulos, D. Terentes-Printzios,
More informationVascular Diseases. Overview: Selected Slides
Vascular Diseases Overview: Selected Slides Total deaths and change in vascular death rates
More information«Πατσζαρκία και Καρδιαγγειακή Νόζος»
«Πατσζαρκία και Καρδιαγγειακή Νόζος» Δημήτρης Π. Παπαδόπουλος-FESC Clinical Assist. Professor George Washington University USA Επιμελητής Καρδιολογικής Κλινικής Π.Γ.Ν.Α. «ΛΑΪΚΟ» Υπεύθυνος Αντιυπερτασικού
More information